New Zealand Passes Medicines Amendment Act to Accelerate Drug Approvals Through International Recognition
核心洞察
New Zealand's Medicines Amendment Act introduces the "Rule of Two" pathway, allowing medicines approved by two recognized overseas jurisdictions to receive approval within 30 days.
The legislation initially recognizes seven jurisdictions including Australia, the United States, Canada, the United Kingdom, the European Union, Singapore and Switzerland for streamlined approvals.
The Act expands prescribing permissions to nurse practitioners, pharmacist prescribers, midwives, dentists, and optometrists within their scope of practice.
New Zealand has enacted the Medicines Amendment Act, introducing streamlined pathways for medicine approvals that could reduce approval times by months. The legislation, which passed Parliament with support from all parties except independent MPs Tākuta Ferris and Mariameno Kapa-Kingi, establishes the "Rule of Two" mechanism allowing medicines to receive ministerial approval within 30 days if they have been approved by two or more recognized overseas regulators.
International Recognition Framework
The Act initially recognizes seven jurisdictions: Australia, the United States, Canada, the United Kingdom, the European Union, Singapore, and Switzerland. These regulators meet specific criteria including operating in regulatory frameworks similar to New Zealand's, conducting business in English, and using international guidelines consistent with New Zealand's approach.
Health Minister Simeon Brown and Associate Health Minister David Seymour highlighted the practical impact of these changes, citing an asthma (搜索) treatment that "could have been approved by the end of 2022 under this pathway but was not approved until 16 months later in May 2024."
The legislation provides flexibility for the Health Minister to add or remove regulators from the approved list through regulatory change without requiring new legislation, provided they meet the specified requirements.
Expanded Prescribing Authority
Beyond approval pathways, the Act significantly expands prescribing permissions to healthcare professionals including nurse practitioners, midwives, dentists, and optometrists, provided the medication falls within their scope of practice. Pharmacist prescribers have also been added to the list of those authorized to prescribe unapproved medicines.
This expansion recognizes "the high clinical skill levels of these professionals and enables medicines to more effectively get to patients," according to legal analysis of the legislation.
Medical Conference Advertising Provisions
A last-minute amendment addresses the advertising of unapproved medicines at medical conferences, resolving legal uncertainties that had emerged during the legislative process. Legal experts had previously warned that advertising unapproved medicines at conferences remained a criminal offense despite ministerial claims to the contrary.
Under the new provisions, conference organizers must notify the Director-General of Health at least 30 working days prior to the conference, providing details including confirmation of unapproved medicine advertising, conference dates and location, regulatory approval status in recognized jurisdictions, and whether New Zealand applications have been submitted.
The ministers estimate this change will generate $90 million in revenue over the next few years while enabling healthcare professionals to "keep up with the latest innovations in health products and medicines."
Implementation and Concerns
The Act represents fulfillment of commitments in National's coalition agreements with both ACT and New Zealand First (搜索). However, the legislation has sparked debate over limited consultation regarding late changes and the new approach of ministerial appointments for the Medical Classification Committee.
Labour's Health spokesperson Ayesha Verrall criticized the ministerial appointment process and suggested the amendments indicate broader challenges with New Zealand's medicines regulation system. "The Medicines Act is from 1981, that is how outdated our medicines regulation is in New Zealand," Verrall stated.
Despite concerns about potential politicization, legal experts view the amendments as "a significant step forward in aligning New Zealand with international best practice" by streamlining approval processes and reducing compliance costs for manufacturers.
The government now awaits introduction of secondary legislation that will outline detailed requirements for the new verification pathway, with implementation monitoring ongoing.